FINWIRES · TerminalLIVE
FINWIRES

$MANE

6 stories mentioning MANEUpdated 24d ago

Every FINWIRES story that references MANE, newest first.

Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.1%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, Novo Nordisk (NVO) shares gained 2.9% after it said Wednesday the European Commission granted marketing authorization for its Wegovy pill for the treatment of adults with obesity or overweight with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.Elevance Health (ELV) reported sequential and annual declines in its Q2 memberships, although the health insurer lifted its full-year earnings outlook and recorded an unexpected year-over-year revenue increase in the previous three-month period. The shares fell past 9%.Veradermics (MANE) shares jumped 12% after the company said its VDPHL01 achieved rapid onset of hair growth with the majority of participants in a phase 2 clinical trial of females with mild-to-moderate pattern hair loss.Eli Lilly-backed (LLY) AdvanCell has raised $315 million from its Series D financing, with participating investors such as Bain Capital and Fidelity Management & Research, Bloomberg reported. Lilly shares were fractionally higher.

$ELV$LLY$MANE$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.1%.The iShares Biotechnology ETF (IBB) added 0.5%.In corporate news, Veradermics (MANE) shares jumped 13% after the company said its VDPHL01 achieved rapid onset of hair growth with the majority of participants in a phase 2 clinical trial of females with mild-to-moderate pattern hair loss.

$MANE
Wire

Update: Veradermics Shares Rise After Potential Female Hair Loss Treatment Restores Hair in Phase 2 Trial

(Updates with recent stock movement in headline and first paragraph.)Veradermics (MANE) shares were up 12% in afternoon trading on Wednesday after the company said its VDPHL01 achieved rapid onset of hair growth with the majority of participants in a phase 2 clinical trial of females with mild-to-moderate pattern hair loss.The orally-administered extended-release formulation showed improvement in hair coverage as early as the second month and "consistent treatment effect" with around 88.9% dosed once a day and 90.0% with those dosed twice a day reporting "improved" or "much improved" results after six months, the company said.VDPHL01 also showed a "favorable" safety and tolerability profile consistent with previous trials, the company said.Veradermics is planning a phase 2/3 clinical trial with results expected in H1 2027, the company said.Price: $123.39, Change: $+13.22, Percent Change: +12.00%

$MANE
Research

B. Riley Initiates Veradermics at Buy With $170 Price Target

Veradermics (MANE) has an average rating of buy and mean price target of $141.60. according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$MANE
Research

Needham Initiates VeraDermics at Buy With $136 Price Target

$MANE
Wire

Top Midday Gainers

Sagimet Biosciences (SGMT) said Monday it has priced an underwritten offering of about 29.2 million shares at $6.00 each to raise about $175 million to help fund its clinical trial.Shares soared 43% as intraday trading volume catapulted to over 45.2 million from a daily average of about 516,000.Veradermics (MANE) said Monday part A of its phase 2/3 trial of VDPHL01 oral pill in males with mild-to-moderate pattern hair loss met all primary and all key secondary endpoints with "high" statistical significance.Shares surged 32%, with intraday trading volume of over 2.5 million from a daily average of roughly 446,000.Oruka Therapeutics (ORKA) jumped 16% after the company said Monday almost 64% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.More than 5.10 million shares traded intraday, compared with a daily average of about 760,000.Price: $8.36, Change: $+2.50, Percent Change: +42.58%

$MANE$OKRA$SGMT

Track with the FINWIRES app suite